Background: Type2 Diabetes mellitus is a progressive disease with multiple pathophysiological defects. If tolerated and not contraindicated metformin as monotherapy is the drug of choice in the diabetic patient. Dual or triple therapy can be considered if glycemic control is not achieved in the three months. Combination drug with complimentary mechanism of action and with lesser adverse events (hypoglycemia, weight gain, cardio-renalevents) can be consider in patients with type 2diabetesmellitus. Methodology: A thorough literature search was performed using PubMed, Google Scholar and Embase. The authors selected the articles based on relevance. T2DM, SGLT2 inhibitors, SGLT2 antagonist, DPP-4 antagonist, DPP-4 inhibitors, dual therapy, add-on therapy were the major searched key words. Result: Through the literature we observed that diabetic patients on monotherapy are at high risk of developing micro and macrovascular complication. Two oral hypoglycemic drugs i.e., sodium glucose cotransporter 2 inhibitor (SGLT2i) and dipeptidyl peptidase 4 inhibitor (DPP-4i) were identified with complementary mechanism of action. Dual (SGLT2i and DPP-4i) therapy or add on therapy to metformin can be used at any phase of diabetes mellitus and are usually well tolerated with lesser side effects. Conclusion: Combination use of SGLT2 inhibitors and DPP-4 inhibitors is attractive because of their complementary mode of action. Dual therapy or add on to metformin should be consider from the initial point of prescribing. Though the precise positioning of a DPP-4i-SGLT2i combination should be better outlined by supplementary studies, this process seems to be a novel choice for the management of patients with T2DM, with a good efficacy/safety ratio but at a higher cost.